Synergistic Anti-Ferroptosis with a Minimalistic, Peroxide-Triggered Carbon Monoxide Donor for Parkinson’s Disease
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02691 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Wenjie Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: Carbon Monoxide, Ferroptosis, Parkinson Disease, Peroxides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, National Key Research and Development Program of China, Science Fund for Distinguished Young Scholars of Jiangsu Province.
Abstract (Originalsprache)
Parkinson’s disease (PD) is a debilitating neurodegenerative disease, with current treatments primarily focusing on improving dopaminergic activity, providing symptomatic relief but failing to halt disease progression. Ferroptosis drives PD pathogenesis and is a potential therapeutic target. Herein, we introduce a novel peroxide-activated carbon monoxide (CO) donor, PCOD, featuring a streamlined structure designed to potentially enhance blood-brain barrier (BBB) penetration and optimize therapeutic outcomes. PCOD releases CO upon activation by nucleophilic peroxides, e.g., ONOO – and H 2 O 2 . This mechanism provides a potent strategy against ferroptosis: first, scavenging peroxides that generate oxidative radicals involved in ferroptosis, and second, CO is proposed to inhibit Fenton chemistry through coordination to Fe 2+ . In MPTP-treated mice, PCOD prevents dopaminergic neuron loss in the substantia nigra and alleviates PD symptoms. This peroxide-triggered CO release offers a promising and innovative strategy to combat ferroptosis and neurodegeneration in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Dongchuan Road 500, Shanghai 200241, China.
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Meilong Road 130, Shanghai 200237, China.
- School of Medical Technology, Xuzhou Key Laboratory of Laboratory Diagnostics, Xuzhou Medical University, Tongshan Road 209, Xuzhou 221004, China.
ORCID-Profile: Linyan Huang, Youjun Yang, Xiao Luo
Förderung
- Natural Science Foundation of Shanghai Municipality
- National Key Research and Development Program of China
- Science Fund for Distinguished Young Scholars of Jiangsu Province
- State Key Laboratory of Bioreactor Engineering
- Xuzhou Medical University
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Program of Shanghai Academic Research Leader
Zitieren
APA
Qin, W., Su, R., Chen, X., Liang, Z., Huang, L., Qian, X., Yang, Y., Qi, S., & Luo, X. (2025). Synergistic Anti-Ferroptosis with a Minimalistic, Peroxide-Triggered Carbon Monoxide Donor for Parkinson’s Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02691
Vancouver
Qin W, Su R, Chen X, Liang Z, Huang L, Qian X, et al. Synergistic Anti-Ferroptosis with a Minimalistic, Peroxide-Triggered Carbon Monoxide Donor for Parkinson’s Disease. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02691
BibTeX
@article{Qin2025,
author = {Qin, Wenjie and Su, Ruiqi and Chen, Xiaodie and Liang, Zhiyan and Huang, Linyan and Qian, Xuhong and Yang, Youjun and Qi, Suhua and Luo, Xiao},
title = {Synergistic Anti-Ferroptosis with a Minimalistic, Peroxide-Triggered Carbon Monoxide Donor for Parkinson’s Disease},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02691}
}
EUVIMED